Literature DB >> 34554905

Vaccines for COVID-19: A Systematic Review of Feasibility and Effectiveness.

Esmaeil Mehraeen1, Omid Dadras2, Amir Masoud Afsahi3, Amirali Karimi4, Mehrzad Mohsseni Pour1, Pegah Mirzapour1, Alireza Barzegary5, Farzane Behnezhad6, Pedram Habibi7, Mohammad Amin Salehi7, Farzin Vahedi4, Mohammad Heydari1, Shaghayegh Kianzad8, Banafsheh Moradmand-Badie9, Mohammad Javaherian10, SeyedAhmad SeyedAlinaghi7, Jean-Marc Sabatier11.   

Abstract

INTRODUCTION: Many potential vaccines for COVID-19 are being studied and developed. Several studies have reported on the safety and efficacy of these vaccines. This systematic review aimed to report on the current evidence concerning the feasibility and effectiveness of vaccines for COVID-19.
METHODS: A systematic search was carried out utilizing the keywords in the online databases, including Scopus, Web of Science, PubMed, Embase, and Cochrane. We included both human and non-human studies because of the vaccine novelty, limiting our ability to include sufficient human studies.
RESULTS: This review showed several SARS-CoV-2 vaccines to be currently under development using different platforms, including eight vaccines that are adenovirus-based vectors, six vaccines that are RNA-based formulations, one vaccine being DNA-based formulation, and other vaccines using other platforms, including lipid nanoparticles. Although the safety and efficacy profiles of these vaccines are still under debate, some countries have allowed for emergency use of some vaccines in at-risk populations, such as healthcare workers and the elderly.
CONCLUSION: It is crucial to gather as much clinically relevant evidence as possible regarding the immunogenicity, efficacy, and safety profiles of available vaccines and adhere wisely to CDC protocols and guidelines for vaccine production. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  COVID-19; SARS-CoV-2; Vaccine; diagnosis; effectiveness; feasibility; immunity; therapy; treatment

Mesh:

Substances:

Year:  2022        PMID: 34554905     DOI: 10.2174/1871526521666210923144837

Source DB:  PubMed          Journal:  Infect Disord Drug Targets        ISSN: 1871-5265


  6 in total

1.  Precision health diagnostic and surveillance network uses S gene target failure (SGTF) combined with sequencing technologies to track emerging SARS-CoV-2 variants.

Authors:  Rafael Guerrero-Preston; Vanessa Rivera-Amill; Karem Caraballo; Sebastian Rodríguez-Torres; Ana Purcell-Wiltz; Andrea A García; Raphael S Torres; Fernando T Zamuner; Claudio Zanettini; Matthew J MacKay; Rachel Baits; Daisy Salgado; Gaurav Khullar; Jessica Metti; Timothy Baker; Joel Dudley; Keilyn Vale; Gabriela Pérez; Lorena De Jesús; Yaima Miranda; Denise Ortiz; Amanda García-Negrón; Liliana Viera; Alberto Ortiz; Jorge A Canabal; Josefina Romaguera; Ivonne Jiménez-Velázquez; Luigi Marchionni; José F Rodríguez-Orengo; Adriana Baez; Christopher E Mason; David Sidransky
Journal:  Immun Inflamm Dis       Date:  2022-06

Review 2.  COVID-19 mortality and its predictors in the elderly: A systematic review.

Authors:  Omid Dadras; SeyedAhmad SeyedAlinaghi; Amirali Karimi; Ahmadreza Shamsabadi; Kowsar Qaderi; Maryam Ramezani; Seyed Peyman Mirghaderi; Sara Mahdiabadi; Farzin Vahedi; Solmaz Saeidi; Alireza Shojaei; Mohammad Mehrtak; Shiva A Azar; Esmaeil Mehraeen; Fabrício A Voltarelli
Journal:  Health Sci Rep       Date:  2022-05-23

3.  Public acceptability of COVID-19 vaccines and its predictors in Middle ‎Eastern/North African (MENA) countries: a systematic review‎.

Authors:  Omid Dadras; SeyedAhmad SeyedAlinaghi; Amirali Karimi; Ahmadreza Shamsabadi; Sara Mahdiabadi; Parsa Mohammadi; Ava Amiri; Alireza Shojaei; Zahra Pashaei; Pegah Mirzapour; Kowsar Qaderi; Mehrzad MohsseniPour; Sanam Alilou; Esmaeil Mehraeen; Shayesteh Jahanfar
Journal:  Hum Vaccin Immunother       Date:  2022-03-23       Impact factor: 4.526

Review 4.  Seroconversion following the first, second, and third dose of SARS-CoV-2 vaccines in immunocompromised population: a systematic review and meta-analysis.

Authors:  Parnian Shobeiri; Mohammad-Mehdi Mehrabi Nejad; Hojat Dehghanbanadaki; Mohammadreza Tabary; Armin Aryannejad; Abdolkarim Haji Ghadery; Mahya Shabani; Fatemeh Moosaie; SeyedAhmad SeyedAlinaghi; Nima Rezaei
Journal:  Virol J       Date:  2022-08-08       Impact factor: 5.913

Review 5.  COVID-19 Vaccines' Protection Over Time and the Need for Booster Doses; a Systematic Review.

Authors:  Omid Dadras; SeyedAhmad SeyedAlinaghi; Amirali Karimi; Alireza Shojaei; Ava Amiri; Sara Mahdiabadi; Amirata Fakhfouri; Armin Razi; Hengameh Mojdeganlou; Paniz Mojdeganlou; Alireza Barzegary; Zahra Pashaei; Amir Masoud Afsahi; Parnian Shobeiri; Esmaeil Mehraeen
Journal:  Arch Acad Emerg Med       Date:  2022-07-04

Review 6.  Minimum infective dose of severe acute respiratory syndrome coronavirus 2 based on the current evidence: A systematic review.

Authors:  SeyedAhmad SeyedAlinaghi; Amirali Karimi; Hengameh Mojdeganlou; Zahra Pashaei; Pegah Mirzapour; Ahmadreza Shamsabadi; Alireza Barzegary; Fatemeh Afroughi; Soheil Dehghani; Nazanin Janfaza; Amirata Fakhfouri; Sepideh Khodaei; Esmaeil Mehraeen; Omid Dadras
Journal:  SAGE Open Med       Date:  2022-08-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.